72220-51-0

Upstream product

• 72220-50-9 2-[4-(trifluoromethoxy)phenoxy]acetic acid 

Downstream Products

• 710328-16-8 N-(2-chloro-4-methylquinolin-6-yl)-2-(4-trifluoromethoxyphenoxy)acetamide 
• 1129693-22-6 (S)-N-(2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide 
• 1248730-06-4 1-{4-[1-(1H-benzotriazole-5-carbonyl)-piperidin-4-yl]-piperazin-1-yl}-2-(4-trifluoromethoxy-phenoxy)-ethanone 
• 1443827-96-0 C₁₉H₁₈F₃NO₄ 
• 1237533-51-5 (3-chlorophenyl)(6,7-dimethoxy-1-((4-(trifluoromethoxy)-phenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone 
• 1443828-11-2 6,7-dimethoxy-1-((4-(trifluoromethoxy)phenoxy)methyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1) has attracted extensive attention as a novel antidiabetic target in the last decade. Several FFA1 agonists reported in the literature have been suffered from relatively high molecular weight and lipophilicity. We have previously reported the FFA1 agonist 1. Based on the common amide structural characteristic of SAR1 and NIH screened compound, we here describe the continued structure-activity exploration to decrease the molecular weight and lipophilicity of the compound 1 series by converting various amide linkers. All of these efforts lead to the discovery of the preferable lead compound 18, a compound with considerable agonistic activity, high LE and LLE values, lower lipophilicity than previously reported agonists, and appreciable efficacy on glucose tolerance in both normal and type 2 diabetic mice.

ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE

The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more s

Treatment of mastitis

The invention provides new fluorinated cephalosporin antibiotics of Formula I wherein Ra, Rb, Rc, Rdand Re, independently, are H, F or a C1-C6alkyl-(Z)n— group having at least one fluorine substituent; X is O or S; Y is S, O, or —CH2—; Z is O, S, —SO—, or —SO2—; m and n independently are 0 or 1; and R1is H, C1-C6-alkyl, phenyl or benzyl, each of which may optionally have up to three substituents selected from halo, C1-C4-alkoxy, phenyl, NO2, C1-C6-alkanoyl, benzoyl, or C1-C6-alkanoyloxy; or a physiologically acceptable salt thereof; and methods of preventing or treating or treating infection, particularly mastitis in ruminants, using these antibiotics.